Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

924 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?
von Amsberg G, Alsdorf W, Karagiannis P, Coym A, Kaune M, Werner S, Graefen M, Bokemeyer C, Merkens L, Dyshlovoy SA. von Amsberg G, et al. Among authors: graefen m. Int J Mol Sci. 2022 Feb 25;23(5):2569. doi: 10.3390/ijms23052569. Int J Mol Sci. 2022. PMID: 35269712 Free PMC article. Review.
Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.
El Gammal AT, Brüchmann M, Zustin J, Isbarn H, Hellwinkel OJ, Köllermann J, Sauter G, Simon R, Wilczak W, Schwarz J, Bokemeyer C, Brümmendorf TH, Izbicki JR, Yekebas E, Fisch M, Huland H, Graefen M, Schlomm T. El Gammal AT, et al. Among authors: graefen m. Clin Cancer Res. 2010 Jan 1;16(1):56-64. doi: 10.1158/1078-0432.CCR-09-1423. Epub 2009 Dec 22. Clin Cancer Res. 2010. PMID: 20028754
Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.
Minner S, Jessen B, Stiedenroth L, Burandt E, Köllermann J, Mirlacher M, Erbersdobler A, Eichelberg C, Fisch M, Brümmendorf TH, Bokemeyer C, Simon R, Steuber T, Graefen M, Huland H, Sauter G, Schlomm T. Minner S, et al. Among authors: graefen m. Clin Cancer Res. 2010 Mar 1;16(5):1553-60. doi: 10.1158/1078-0432.CCR-09-2546. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179235
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Müller J, Scholz L, Brase JC, Liu AY, Schlüter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T. Minner S, et al. Among authors: graefen m. Clin Cancer Res. 2011 Sep 15;17(18):5878-88. doi: 10.1158/1078-0432.CCR-11-1251. Epub 2011 Jul 26. Clin Cancer Res. 2011. PMID: 21791629
Marked heterogeneity of ERG expression in large primary prostate cancers.
Minner S, Gärtner M, Freudenthaler F, Bauer M, Kluth M, Salomon G, Heinzer H, Graefen M, Bokemeyer C, Simon R, Sauter G, Schlomm T, Wilczak W. Minner S, et al. Among authors: graefen m. Mod Pathol. 2013 Jan;26(1):106-16. doi: 10.1038/modpathol.2012.130. Epub 2012 Aug 17. Mod Pathol. 2013. PMID: 22899295 Free article.
Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse.
Hennigs JK, Müller J, Adam M, Spin JM, Riedel E, Graefen M, Bokemeyer C, Sauter G, Huland H, Schlomm T, Minner S. Hennigs JK, et al. Among authors: graefen m. PLoS One. 2014 Jul 10;9(7):e100469. doi: 10.1371/journal.pone.0100469. eCollection 2014. PLoS One. 2014. PMID: 25010045 Free PMC article.
924 results